IDT enters IVD market
What happened
Integrated DNA Technologies announced IVD offerings — Archer FUSIONPlex™‑HT Dx and VARIANTPlex™‑HT Dx — signaling a push into NGS-based molecular pathology tools marketed for compliant diagnostics. That move may expand vendor options for labs building NGS capacity from cytology and small-aspirate samples. (x.com/idtdna/status/2038638489852366861)
Why it matters
Made available March 23, 2026, the IVD kits are being distributed in the United States and in select European countries as part of IDT’s initial clinical‑grade rollout. (idtdna.com) Both Dx offerings are built on IDT’s patented Anchored Multiplex PCR (AMP™) chemistry, a target‑enrichment method that enables fusion detection without prior knowledge of the fusion partner and is optimized for low‑input and FFPE specimens. (idtdna.com) IDT’s product description states each kit ships with color‑coded, technician‑ and robot‑friendly reagents, adapters, and magnetic cleanup beads and that key workflow steps can be run in parallel to streamline library preparation. (idtdna.com) IDT acquired the Archer NGS research‑assay portfolio from Invitae in December 2022 for roughly $48 million, a transaction that brought VariantPlex, FusionPlex, LiquidPlex, and Immunoverse assets into IDT’s NGS lineup. (businesswire.com) Technical materials from IDT and archived Archer documentation confirm VARIANTPlex and FUSIONPlex panels can be paired to interrogate DNA and RNA from a single sample for combined SNV/indel/CNV profiling plus fusion detection. (idtdna.com) IDT characterized the Dx launch as the first of multiple planned diagnostic product rollouts and said the roadmap will extend Archer IVD capabilities toward novel fusion and complex‑variant detection for challenging sample types. (idtdna.com)
Key numbers
- (x.com/idtdna/status/2038638489852366861) Made available March 23, 2026, the IVD kits are being distributed in the United States and in select European countries as part of IDT’s initial clinical‑grade rollout.
- (idtdna.com) IDT acquired the Archer NGS research‑assay portfolio from Invitae in December 2022 for roughly $48 million, a transaction that brought VariantPlex, FusionPlex, LiquidPlex, and Immunoverse assets into IDT’s NGS lineup.
What happens next
- (idtdna.com) Both Dx offerings are built on IDT’s patented Anchored Multiplex PCR (AMP™) chemistry, a target‑enrichment method that enables fusion detection without prior knowledge of the fusion partner and is optimized for low‑input and FFPE specimens.
- (idtdna.com) IDT characterized the Dx launch as the first of multiple planned diagnostic product rollouts and said the roadmap will extend Archer IVD capabilities toward novel fusion and complex‑variant detection for challenging sample types.
- That move may expand vendor options for labs building NGS capacity from cytology and small-aspirate samples.
Quick answers
What happened in IDT enters IVD market?
Integrated DNA Technologies announced IVD offerings — Archer FUSIONPlex™‑HT Dx and VARIANTPlex™‑HT Dx — signaling a push into NGS-based molecular pathology tools marketed for compliant diagnostics. That move may expand vendor options for labs building NGS capacity from cytology and small-aspirate samples. (x.com/idtdna/status/2038638489852366861)
Why does IDT enters IVD market matter?
Made available March 23, 2026, the IVD kits are being distributed in the United States and in select European countries as part of IDT’s initial clinical‑grade rollout. (idtdna.com) Both Dx offerings are built on IDT’s patented Anchored Multiplex PCR (AMP™) chemistry, a target‑enrichment method that enables fusion detection without prior knowledge of the fusion partner and is optimized for low‑input and FFPE specimens. (idtdna.com) IDT’s product description states each kit ships with color‑coded, technician‑ and robot‑friendly reagents, adapters, and magnetic cleanup beads and that key workflow steps can be run in parallel to streamline library preparation. (idtdna.com) IDT acquired the Archer NGS research‑assay portfolio from Invitae in December 2022 for roughly $48 million, a transaction that brought VariantPlex, FusionPlex, LiquidPlex, and Immunoverse assets into IDT’s NGS lineup. (businesswire.com) Technical materials from IDT and archived Archer documentation confirm VARIANTPlex and FUSIONPlex panels can be paired to interrogate DNA and RNA from a single sample for combined SNV/indel/CNV profiling plus fusion detection. (idtdna.com) IDT characterized the Dx launch as the first of multiple planned diagnostic product rollouts and said the roadmap will extend Archer IVD capabilities toward novel fusion and complex‑variant detection for challenging sample types. (idtdna.com)
